Literature DB >> 2255232

Development of the "activated" high resolution 1H MR spectrum in murine T cells and B cells occurs in G1 phase of the cell cycle.

K T Holmes1, C L Lean, N H Hunt, N J King.   

Abstract

T and B lymphocytes stimulated with mitogens develop 1H MR spectra characteristic of triglycerides in an isotropic environment. These distinctive signals, which are also observed in malignant cells, cannot be suppressed by compounds which inhibit progression through the cell cycle. Cellular proliferation is thus not essential for the development and maintenance of high resolution lipid spectra in activated cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2255232     DOI: 10.1002/mrm.1910160102

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  5 in total

1.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

Authors:  D H Miller; F Barkhof; I Berry; L Kappos; G Scotti; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

Review 2.  MR-visible lipids and the tumor microenvironment.

Authors:  E James Delikatny; Sanjeev Chawla; Daniel-Joseph Leung; Harish Poptani
Journal:  NMR Biomed       Date:  2011-04-27       Impact factor: 4.044

3.  Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.

Authors:  J J Raizer; J A Koutcher; L E Abrey; K S Panageas; L M DeAngelis; E Lis; S Xu; K L Zakian
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

4.  Triglyceride blisters in lipid bilayers: implications for lipid droplet biogenesis and the mobile lipid signal in cancer cell membranes.

Authors:  Himanshu Khandelia; Lars Duelund; Kirsi I Pakkanen; John H Ipsen
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

5.  Cell and membrane lipid analysis by proton magnetic resonance spectroscopy in five breast cancer cell lines.

Authors:  L Le Moyec; R Tatoud; M Eugène; C Gauvillé; I Primot; D Charlemagne; F Calvo
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.